| Biomarker ID | 1466 |
| PMID | 25057439 |
| Year | 2014 |
| Biomarker | High Mobility Group Box 1 (HMGB1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Distant Metastases |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Endogenous Toll-like receptor signaling, Interferon-beta enhancer pathway, Base excision repair, Beta-3 integrin cell surface interactions, TAK1 activates NF-kappaB by phosphorylation and activation of IKK complex |
| Experiment | Distant Metastases Vs No Distant Metastases |
| Type of Biomarker | Prognostic |
| Cohort | 85 patients with prostate cancer and 30 with Benign prostatic hyperplasia were selected for the analysis. 44 did not have distant metastatis and 41 did have Distant Metastatis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.019 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |